Biomarkers for parotid cancer; grade diagnosis and personalized treatment by abnormal gene

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K09641
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56050:Otorhinolaryngology-related
• Research Institution: Osaka Medical and Pharmaceutical University
• Principal Investigator: Kawata Ryo 大阪医科薬科大学, 医学部, 教授 (40224787)
• Co-Investigator(Kenkyū-buntansha): 栗栖 義賢 大阪医科薬科大学, 医学部, 准教授 (30319529)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 耳下腺癌 / 悪性度 / HER2 / AR / 組織型 / 生存率 / 新規治療 / 個別化治療

Outline of Final Research Achievements

The subjects were 268 patients with parotid carcinoma treated at our department during the 24-year. The 5-year disease-specific survival rate (DSS) was 100% for patients in stage I, 98.6% in stage II, 85.0% in stage III, and 56.9% in stage IV. 30 patients were human epidermal growth factor receptor type 2 (HER2) positive. 35 patients were androgen receptor (AR) positive. Immunohistological investigation showed patients with HER-2 or AR-positive tumors had a significantly worse prognosis. PD-L1 expression was found in 34.6% of parotid carcinomas, with the expression being higher in tumors with a higher stage and a higher grade. The 5-year DSS in grade and stage showed no significant difference. The 10-year DSS rates were as follows: MEC, 34.9%; SDC, 22.6%; CXPA, 47.1%; and AdCC, 56.3%. Each histological type was found to have its own pathological and clinical features, so diagnosis, treatment, and follow-up should be performed accordingly.

Free Research Field

頭頸部腫瘍

Academic Significance and Societal Importance of the Research Achievements

耳下腺癌の予後は必ずしも良好ではなく、現状では手術以外に有効な手段がない。また顔面神経が耳下腺内を走行しており、その温存・切除により術後の生活に質（QOL）を大きく左右する。今回の研究において耳下腺癌に対して、組織別、悪性度別の腫瘍特性を探索することおよびバイオマーカーから新規薬物治療の可能性を見出すことが、生命予後の改善だけでなく患者のQOLに大きく貢献できると考えられる。多彩である耳下腺癌に対する個別化治療を確立することが最終目標である。